epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Imuldosa (ustekinumab-srlf)
    ustekinumab
  • remove Jylamvo
    methotrexate
  • remove Selarsdi (ustekinumab-aekn)
    ustekinumab
  • remove Spevigo (spesolimab-sbzo)
    spesolimab
  • remove Steqeyma (ustekinumab-stba)
    ustekinumab

multicheck MultiCheck Results - 7 Interactions

Smiley face Smiley face

Caution Advised

Smiley face Smiley face Imuldosa (ustekinumab-srlf) (ustekinumab) + Jylamvo (methotrexate)

Caution Advised


ustekinumab + methotrexate

caution advised: combo may incr. risk of serious infection (additive effects)

Smiley face Smiley face Imuldosa (ustekinumab-srlf) (ustekinumab) + Spevigo (spesolimab-sbzo) (spesolimab)

Caution Advised


ustekinumab + spesolimab

caution advised: combo may incr. risk of serious infection (additive effects)

Smiley face Smiley face Jylamvo (methotrexate) + Selarsdi (ustekinumab-aekn) (ustekinumab)

Caution Advised


methotrexate + ustekinumab

caution advised: combo may incr. risk of serious infection (additive effects)

Smiley face Smiley face Jylamvo (methotrexate) + Spevigo (spesolimab-sbzo) (spesolimab)

Caution Advised


methotrexate + spesolimab

caution advised: combo may incr. risk of serious infection (additive effects)

Smiley face Smiley face Jylamvo (methotrexate) + Steqeyma (ustekinumab-stba) (ustekinumab)

Caution Advised


methotrexate + ustekinumab

caution advised: combo may incr. risk of serious infection (additive effects)

Smiley face Smiley face Selarsdi (ustekinumab-aekn) (ustekinumab) + Spevigo (spesolimab-sbzo) (spesolimab)

Caution Advised


ustekinumab + spesolimab

caution advised: combo may incr. risk of serious infection (additive effects)

Smiley face Smiley face Spevigo (spesolimab-sbzo) (spesolimab) + Steqeyma (ustekinumab-stba) (ustekinumab)

Caution Advised


spesolimab + ustekinumab

caution advised: combo may incr. risk of serious infection (additive effects)

Additional Considerations

Smiley face Smiley face ustekinumab in Imuldosa (ustekinumab-srlf), Selarsdi (ustekinumab-aekn), Steqeyma (ustekinumab-stba)

caution advised w/ narrow therapeutic index drugs; chronic inflammatory conditions may alter metabolic enzyme formation; tx w/ immune modulators may reverse this effect, resulting in altered levels of concomitant drugs

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information